Further research is needed to investigate these results, and the results of the drug sensitivity analysis indicated that IGLL1, SLAMF7, SLAMF1, CD48, and LRRC8A might decrease sensitivity to specific chemotherapy drugs, further affecting the treatment efficacy for breast cancer. This evidence concerns the gene SLAMF1 and breast carcinoma.